Erythroid induction of K562 cells treated with mithramycin is associated with inhibition of raptor gene transcription and mammalian target of rapamycin complex 1 (mTORC1) functions

Autor: Jessica Gasparello, Monica Borgatti, Roberto Gambari, Giulia Breveglieri, Enrica Fabbri, Nicoletta Bianchi, Alessia Finotti
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Sp1
specific protein 1

EMSA
electrophoretic mobility shift assay

Cellular differentiation
Gene Expression
mTORC1
0302 clinical medicine
Mithramycin
hemic and lymphatic diseases
Gene expression
TBS
tris-buffered saline

Promoter Regions
Genetic

Erythroid induction
MTH
mithramycin

0303 health sciences
TOR Serine-Threonine Kinases
Rictor
rapamycin-insensitive companion of mTOR

Cell Cycle
Cell Differentiation
Plicamycin
Fetal hemoglobin
Pyrrolidonecarboxylic Acid
3. Good health
Raptor
ChIP
chromatin immunoprecipitation

Raptor
mTOR
Sp1
Mithramycin
Erythroid induction
Fetal hemoglobin

030220 oncology & carcinogenesis
mTOR
ODN
oligonucleotide

Oligopeptides
HbF
fetal hemoglobin

Sp1
PBS
phosphate-buffered saline

P70-S6 Kinase 1
mTOR
mammalian target of rapamycin

Mechanistic Target of Rapamycin Complex 1
Biology
Article
NO
03 medical and health sciences
FBS
fetal bovine serum

Humans
m-TORC2
mTOR complex 2

RNA
Messenger

PI3K/AKT/mTOR pathway
ComputingMethodologies_COMPUTERGRAPHICS
Adaptor Proteins
Signal Transducing

030304 developmental biology
Pharmacology
Sp1 transcription factor
Raptor
regulatory associated protein of mTOR

RAPA
rapamycin

Regulatory-Associated Protein of mTOR
Molecular biology
Rapamycin-Insensitive Companion of mTOR Protein
Multiprotein Complexes
mTORC1
mTOR complex 1

Carrier Proteins
K562 Cells
Chromatin immunoprecipitation
K562 cells
Zdroj: Pharmacological Research
Popis: Graphical abstract
Rapamycin, an inhibitor of mTOR activity, is a potent inducer of erythroid differentiation and fetal hemoglobin production in β-thalassemic patients. Mithramycin (MTH) was studied to see if this inducer of K562 differentiation also operates through inhibition of mTOR. We can conclude from the study that the mTOR pathway is among the major transcript classes affected by mithramycin-treatment in K562 cells and a sharp decrease of raptor protein production and p70S6 kinase is detectable in mithramycin treated K562 cells. The promoter sequence of the raptor gene contains several Sp1 binding sites which may explain its mechanism of action. We hypothesize that the G + C-selective DNA-binding drug mithramycin is able to interact with these sequences and to inhibit the binding of Sp1 to the raptor promoter due to the following results: (a) MTH strongly inhibits the interactions between Sp1 and Sp1-binding sites of the raptor promoter (studied by electrophoretic mobility shift assays, EMSA); (b) MTH strongly reduces the recruitment of Sp1 transcription factor to the raptor promoter in intact K562 cells (studied by chromatin immunoprecipitation experiments, ChIP); (c) Sp1 decoy oligonucleotides are able to specifically inhibit raptor mRNA accumulation in K562 cells. In conclusion, raptor gene expression is involved in mithramycin-mediated induction of erythroid differentiation of K562 cells and one of its mechanism of action is the inhibition of Sp1 binding to the raptor promoter.
Databáze: OpenAIRE